Based on
cell-penetrating peptide technology research, we aim to lead in improving the quality of life
REMEDI specializes in the development of novel treatments for cancer, atopic dermatitis, and brain diseases.
Using our AI-based Intra-celluar Drug Delivery Tecnology (IDDT) platform, we discovers peptides that can boost efficacy and mitigate toxicity by delivering various biomolecules such as proteins, antibodies, RNA, and DNA.
Our primary commitment is to validate the therapeutic potential of peptides indentified through our IDDT platform via rigorous testing and their subsequent application in disease-specific models. Every member of our executive team and staff is dedicated to advancing the human condition by pioneering effective and groundbreaking pharmaceuticals.
We aspire to evolve into a company that profoundly impacts the lives of all individuals, contributing to a better quality of life for humanity as a whole.
CEO Chanho Park
Introducing
the CEO’s profile
Key history
- Graduated from University of Washington Department of Chemistry
- Master's degree in Molecular Medicine and Biopharmaceuticals, Seoul National University Graduate School
- Chief researcher, Hypoxic Targeted Disease Research Center
- Senior researcher at MBD Co., Ltd.
- Current CEO of REMEDI Co., Ltd.
Career highlights
- Development of peptide treatments for kidney cancer
- Exploration of cellular aging mechanisms
- Joint research and development of cancer treatment peptides based on clinical database with Samsung Seoul Hospital
- Collaborative research with various universities (Chung-Ang University, Hallym University, Sahmyook University, etc.)
- Received National R&D grants
- Publication of SCI-level papers